Literature DB >> 34126426

Experimentally exploring the potential behavioral effects of personalized genetic information about marijuana and schizophrenia risk.

Matthew S Lebowitz1, Paul S Appelbaum2, Lisa B Dixon2, Ragy R Girgis2, Melanie M Wall2.   

Abstract

Marijuana use may increase schizophrenia risk, and this effect may be genetically moderated. We investigated how hypothetical genetic test results indicating the presence or absence of heightened schizophrenia risk in reaction to marijuana use would affect attitudes toward marijuana use. In two experiments, participants were randomized to hypothetical scenarios in which genetic testing showed the presence or absence of a predisposition for marijuana use to increase their schizophrenia risk, or to a control condition with no mention of genetic testing. Experiment 1 used a sample of 801 U.S. young adults recruited via Amazon.com's Mechanical Turk platform. Experiment 2 replicated the same procedures with a nationally representative sample of 800 U.S. adults aged 18-30. In Experiment 1, those in the predisposition condition, compared to the control condition, rated the likelihood and importance of their avoiding marijuana as significantly higher, whereas those in the no-predisposition condition rated both as significantly lower. In experiment 2, these findings were largely replicated for the predisposition condition but not the no-predisposition condition, and prior marijuana use was a significant moderator, with the effects of the predisposition condition confined to participants who reported having used marijuana. If these results are predictive of responses to actual genetic testing, they suggest that genetic test results indicating that marijuana use will increase one's schizophrenia risk may incentivize abstinence, especially for those with prior marijuana use. Future research could further investigate whether genetic test results indicating the absence of such a predisposition might disincentivize abstinence from marijuana use.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Behavioral intentions; Health psychology; Locus of control; Psychosis; Self-efficacy; Substance use

Mesh:

Year:  2021        PMID: 34126426      PMCID: PMC8319095          DOI: 10.1016/j.jpsychires.2021.05.066

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   5.250


  19 in total

Review 1.  Cannabis-associated psychosis: Neural substrate and clinical impact.

Authors:  R M Murray; A Englund; A Abi-Dargham; D A Lewis; M Di Forti; C Davies; M Sherif; P McGuire; D C D'Souza
Journal:  Neuropharmacology       Date:  2017-06-17       Impact factor: 5.250

2.  National Estimates of Marijuana Use and Related Indicators - National Survey on Drug Use and Health, United States, 2002-2014.

Authors:  Alejandro Azofeifa; Margaret E Mattson; Gillian Schauer; Tim McAfee; Althea Grant; Rob Lyerla
Journal:  MMWR Surveill Summ       Date:  2016-09-02

Review 3.  Gene-environment interplay in the etiology of psychosis.

Authors:  Alyson Zwicker; Eileen M Denovan-Wright; Rudolf Uher
Journal:  Psychol Med       Date:  2018-01-15       Impact factor: 7.723

4.  Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Samantha L Leaf; Wendy Kohlmann; Sancy A Leachman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-15       Impact factor: 4.254

5.  Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users.

Authors:  Marta Di Forti; Conrad Iyegbe; Hannah Sallis; Anna Kolliakou; M Aurora Falcone; Alessandra Paparelli; Miriam Sirianni; Caterina La Cascia; Simona A Stilo; Tiago Reis Marques; Rowena Handley; Valeria Mondelli; Paola Dazzan; Carmine Pariante; Anthony S David; Craig Morgan; John Powell; Robin M Murray
Journal:  Biol Psychiatry       Date:  2012-07-24       Impact factor: 13.382

6.  Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia.

Authors:  Nathan A Gillespie; Kenneth S Kendler
Journal:  JAMA Psychiatry       Date:  2021-05-01       Impact factor: 21.596

7.  Cannabis use and risk of schizophrenia: a Mendelian randomization study.

Authors:  J Vaucher; B J Keating; A M Lasserre; W Gan; D M Lyall; J Ward; D J Smith; J P Pell; N Sattar; G Paré; M V Holmes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

Review 8.  Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.

Authors:  Arianna Marconi; Marta Di Forti; Cathryn M Lewis; Robin M Murray; Evangelos Vassos
Journal:  Schizophr Bull       Date:  2016-02-15       Impact factor: 9.306

Review 9.  Theory of planned behavior and smoking: meta-analysis and SEM model.

Authors:  Gabriela Topa; Juan Antonio Moriano
Journal:  Subst Abuse Rehabil       Date:  2010-12-06

Review 10.  The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis.

Authors:  Gareth J Hollands; David P French; Simon J Griffin; A Toby Prevost; Stephen Sutton; Sarah King; Theresa M Marteau
Journal:  BMJ       Date:  2016-03-15
View more
  2 in total

1.  COVID-19, Genetics, and Risk: Content Analysis of Facebook Posts Early in the Coronavirus Pandemic.

Authors:  Heather E Canary; Natalie Wellman; Lourdes S Martinez
Journal:  Health Commun       Date:  2022-01-23

2.  Perceptions of causal attribution and attitudes to genetic testing among people with schizophrenia and their first-degree relatives.

Authors:  Melissa B R Cullen; Bettina Meiser; Kristine Barlow-Stewart; Melissa Green; Paul S Appelbaum; Vaughan J Carr; Murray J Cairns; M S Lebowitz; Rajneesh Kaur
Journal:  Eur J Hum Genet       Date:  2022-05-16       Impact factor: 5.351

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.